NCL Method GTA-13

By Stephan Stern

In Vitro Blood Partitioning Assay

Listed in Datasets | publication by group NCL Protocols

Version 1.0 - published on 04 May 2020 doi:10.17917/ZMDT-FP49 - cite this

Licensed under these terms

Description

Characterization of drug release under physiological conditions is very important for prediction of drug release in vivo, and can be used for formulation optimization. This assay uses a blood partitioning technique to measure the release of free drug from a nanoparticle-encapsulated drug complex. This assay is based on the principle that the free drug will partition between the plasma and red blood cell (RBC) fractions, whereas the hydrophilic nanoparticle platform is generally retained in the plasma fraction.

 

The protocol is written for analysis of a dual radioactively labeled drug-nanoparticle platform complex (i.e. 14C-labeled drug and 3H-labeled nanoparticle platform). The protocol can also be adapted to use non-radioactive materials, provided that suitable analytical methods can be developed to measure both the drug and platform components independently in blood and plasma matrix (i.e. ICP-MS for the nanoparticle platform component and HPLC for the drug component). The same principles outlined in the study design below could be used for these non-radioactive analytical methods.

Content List

Cite this work

Researchers should cite this work as follows:

Tags

Recommendations

Powered by ...

NCL Protocols

NCL Protocols group image

When watching a publication, you will be notified when a new version is released.